Eli Lilly partnered with Hong Kong drugmaker METiS TechBio in an AI-driven research deal focused on improving lipid nanoparticle (LNP) drug delivery. The collaboration is designed to use AI to propose new LNP formulations capable of tissue-specific delivery. LNPs are central to the durability and potency of RNA-based therapies and other genetic medicines, but tissue targeting remains a key bottleneck. Under the agreement, Lilly could make payments of up to $1.1 billion, though the size of milestone-based tranches was not disclosed in the summary. For the biotech industry, the structure signals that large pharma is increasingly underwriting AI-enabled formulation discovery—shifting some competitive advantage from payload-only innovation toward platform delivery control.